Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 23, 2007

Microchip Biotechnologies Secures IP Related to Microfluidic Devices

  • Microchip Biotechnologies (MBI) gained rights to commercialize a University of Alberta invention that can improve lab-on-a-chip devices and biosampling procedures.

    A team led by Jed Harrison, professor and chair in the department of chemistry, developed the technology to allow trapping of beads on-chip as well as packing and unpacking the trapping zones. These innovations significantly extend the applications of microfluidic analysis systems, according to Harrison.

    The exclusive patent license agreement was carried out through TEC Edmonton, the technology transfer office for the University.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »